Deutsche Bank initiated coverage of ImmunoGen with a Buy rating and $25 price target. The analyst says Elahere is positioning itself to be the new standard of care for FR alpha-positive ovarian cancer. The firm notes full data for Elahere’s PICCOLO trial for late-line platinum-sensitive ovarian cancer patients reads out mid-2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IMGN:
